Molecular and Cellular Biochemistry

, Volume 337, Issue 1–2, pp 145–152 | Cite as

Polymorphisms of IL-6 174 G/C, IL-10 -592 C/A and risk of HIV/AIDS among North Indian population

  • Ranbir Chander Sobti
  • Nega Berhane
  • Salih Abdul Mahedi
  • Rupinder Kler
  • Seyed Ali Hosseini
  • Vijish Kuttiat
  • Ajay Wanchu
Article

Abstract

A growing body of evidence suggests that host genetic factors play an important role both in susceptibility to HIV infection and progression to AIDS. The present study aimed at evaluating the role of IL-6 and IL-10 gene polymorphisms on the risk of HIV susceptibility and disease progression among North Indian patients. The polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) techniques were applied to genotype IL-6 and IL-10. 300 seropositive and an equal number of age- and sex-matched seronegative control subjects were recruited for this study. There was statistically no significant variation in the frequencies of IL-6 and IL-10 genotypes among cases and controls. However, statistically non-significant association for risk of rapid disease progression was observed due to the combined effect of the IL-6 homozygous CC genotype and CC of IL-10, OR = 1.62, 95% CI = 0.38–6.91. Therefore, combined effects of the CC of IL-6 and CC of IL-10 might reduce the hosts ability to hinder viral replication after infection.

Keywords

HIV AIDS Disease progression IL-6 IL-10 PCR RFLP 

References

  1. 1.
    AIDS epidemic update (2008). http://www.unaids.org. Accessed on 12 Jan 2009
  2. 2.
    Godbole S, Mehendale S (2005) HIV/AIDS epidemic in India: risk factors. Risk behaviour & strategies for prevention & control. Indian J Med Res 121:356–368PubMedGoogle Scholar
  3. 3.
    Michael NL (2002) Host genetics and HIV—removing the mask. Nat Med 8:783–785CrossRefPubMedGoogle Scholar
  4. 4.
    Ward JW, Bush TJ, Perkins HA, Lieb LE, Allen JR, Goldfinger D, Samson SM, Pepkowitz SH, Fernando LP, Holland PV, Kleinman SH, Grindon AJ, Graner PA, Rutherford GW, Holmberg SD (1989) The natural history of transfusion-associated infection with human immunodeficiency virus. Factors influencing the rate of progression to disease. N Engl J Med 321:947–952PubMedGoogle Scholar
  5. 5.
    Fowke KR, Nagelkerke ND, Kimani J, Simonsen JN, Anzala AO, Bwayo JJ, McDonald KS, Ngugi EN, Plummer FA (1996) Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Plummer. Lancet 348:1347–1351CrossRefPubMedGoogle Scholar
  6. 6.
    Rowland-Jones SL, McMichael A (1995) Immune responses in HIV-exposed seronegatives: have they repelled the virus? Curr Opin Immunol 7:448–455CrossRefPubMedGoogle Scholar
  7. 7.
    Shearer GM, Clerici M (1996) Protective immunity against HIV infection: has nature done the experiment for us? Immunol Today 17:21–24CrossRefPubMedGoogle Scholar
  8. 8.
    Heeney J, Beverley P, McMichael A, Shearer G, Strominger J, Wahren B, Weber J, Gotch F (1999) Immune correlates of protection from HIV and AIDS—more answers but yet more questions. Immunol Today 20:247–251CrossRefPubMedGoogle Scholar
  9. 9.
    Kulkarni PS, Butera ST, Duerr AC (2003) Resistance to HIV-1 infection: lessons learned from studies of highly exposed persistently seronegative (HEPS) individuals. AIDS Rev 5:87–103PubMedGoogle Scholar
  10. 10.
    Nowak MA, Anderson RM, McLeann AR, Wolfs TF, Goudsmit J, May RM (1991) Antigenic diversity thresholds and the development of AIDS. Science 254:963–969CrossRefPubMedGoogle Scholar
  11. 11.
    Biggar RJ (1990) AIDS incubation in 1981 HIV seroconverters from different exposure groups. AIDS 4:1059–1065CrossRefPubMedGoogle Scholar
  12. 12.
    Kishimoto T, Akira S, Taga T (1992) Interleukin-6 and its receptor: a paradigm for cytokines. Science 258:593–597CrossRefPubMedGoogle Scholar
  13. 13.
    Pasic J, Levy WC, Sullivan MD (2003) Cytokines in depression and heart failure. Psychosom Med 65:181–193CrossRefPubMedGoogle Scholar
  14. 14.
    Ramadori G, Christ B (1999) Cytokines and the hepatic acute-phase response. Semin Liver Dis 19:141–155CrossRefPubMedGoogle Scholar
  15. 15.
    Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, Woo P (1998) The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 102:1369–1376CrossRefPubMedGoogle Scholar
  16. 16.
    McNicholl JM, Smith DK, Qari SH, Hodge T (1997) Host genes and HIV: the role of the chemokine receptor gene CCR5 and its allele. Emerg Infect Dis 3:3261–3271CrossRefGoogle Scholar
  17. 17.
    O’Brien SJ, Dean M (1997) In search of AIDS-resistance genes. Sci Am 277:44–51CrossRefPubMedGoogle Scholar
  18. 18.
    Mocellin S, Marincola FM, Young HA (2005) Interleukin-10 and the immune response against cancer: a counterpoint. J Leukoc Biol 78:1043–1105CrossRefPubMedGoogle Scholar
  19. 19.
    Del Prete G, De Carli M, Almerigogna F, Giudizi MG, Biagiotti R, Romagnani S (1993) Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. J Immunol 150:353–360PubMedGoogle Scholar
  20. 20.
    Westendorp RG, Langermans JA, Huizinga TW, Verweij CL, Sturk A (1997) Genetic influence on cytokine production in meningococcal disease. Lancet 349:1912–1913CrossRefPubMedGoogle Scholar
  21. 21.
    Eskdale J, Keijsers V, Huizinga T, Gallagher G (1999) Microsatellite alleles and single nucleotide polymorphisms (SNP) combine to form four major haplotype families at the human interleukin-10 (IL-10) locus. Genes Immun 1:151–155CrossRefPubMedGoogle Scholar
  22. 22.
    Langsenlehner U, Krippl P, Renner W, Yazdani-Biuki B, Eder T, Köppel H, Wascher TC, Paulweber B, Samonigg H (2005) Interleukin-10 promoter polymorphism is associated with decreased breast cancer risk. Breast Cancer Res Treat 90:113–115CrossRefPubMedGoogle Scholar
  23. 23.
    De Michele A, Martin AM, Mick R, Gor P, Wray L, Klein-Cabral M, Athanasiadis G, Colligan T, Stadtmauer E, Weber B (2003) Interleukin-6–174G→C polymorphism is associated with improved outcome in high-risk breast cancer. Cancer Res 63:8051–8056Google Scholar
  24. 24.
    Humphries SE, Luong LA, Ogg MS, Hawe E, Miller GJ (2001) The interleukin-6-174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men. Eur Heart J 22:2243–2252CrossRefPubMedGoogle Scholar
  25. 25.
    Cavet J, Dickinson AM, Norden J, Taylor PR, Jackson GH, Middleton PG (2001) Interferon-γ and interleukin-6 gene polymorphisms associate with graft-versus host disease in HLA-matched sibling bone marrow transplantation. Blood 98:1594–1600CrossRefPubMedGoogle Scholar
  26. 26.
    Hulkkonen J, Pertovaara M, Antonen J, Pasternack A, Hurme M (2001) Elevated interleukin-6 plasma levels are regulated by the promoter region polymorphism of the IL6 gene in primary Sjogren’s syndrome and correlate with the clinical manifestations of the disease. Rheumatology 40:656–661CrossRefPubMedGoogle Scholar
  27. 27.
    Pecoits-Filho R, Lindholm B, Axelsson J, Stenvinkel P (2003) Update on interleukin-6 and its role in chronic renal failure. Nephrol Dial Transplant 18:1042–1045CrossRefPubMedGoogle Scholar
  28. 28.
    Bologa RM, Levine DM, Parker TS, Cheigh JS, Serur D, Stenzel KH, Rubin AL (1998) Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 32:107–114CrossRefPubMedGoogle Scholar
  29. 29.
    Cox ED, Hoffmann SC, DiMercurio BS, Wesley RA, Harlan DM, Kirk AD, Blair PJ (2001) Cytokine polymorphic analyses indicate ethnic differences in the allelic distribution of interleukin-2 and interleukin-6. Transplantation 72:720–772CrossRefPubMedGoogle Scholar
  30. 30.
    Terry CF, Loukaci V, Green FR (2000) Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem 275:18138–18144CrossRefPubMedGoogle Scholar
  31. 31.
    Vickers MA, Green FR, Terry C, Mayosi BM, Julier C, Lathrop M, Ratcliffe PJ, Watkins HC, Keavney B (2002) Genotype at a promoter polymorphism of the interleukin-6 gene is associated with baseline levels of plasma C-reactive protein. Cardiovasc Res 53:1029–1034CrossRefPubMedGoogle Scholar
  32. 32.
    Matsuda M, Salazar F, Petersson M, Masucci G, Hansson J, Pisa P, Zhang QJ, Masucci MG, Kiessling R (1994) Interleukin 10 pretreatment protects target cells from tumor- and allospecific cytotoxic T cells and downregulates HLA class I expression. J Exp Med 120:2371–2376CrossRefGoogle Scholar
  33. 33.
    Fortis C, Foppoli M, Gianotti L, Galli L, Citterio G, Consogno G, Gentilini O, Bragaet M (1996) Increased interleukin-10 serum levels in patients with solid tumours. Cancer Lett 104:1–5CrossRefPubMedGoogle Scholar
  34. 34.
    Zhang X, Hei P, Deng L, Lin J (2007) Interleukin-10 gene promoter polymorphisms and their protein production in peritoneal fluid in patients with endometriosis. Mole Hum Reprod 13:135–140CrossRefGoogle Scholar
  35. 35.
    Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV (1998) An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 24:1–8Google Scholar
  36. 36.
    van der Poll T, Marchant A, Koeogh CV, Goldman M, Lowry SF (1996) Interleukin-10 impairs host defense in murine pneumococcal pneumonia. J Infect Dis 174:994–1000PubMedGoogle Scholar
  37. 37.
    Greenberger MJ, Strieter RM, Kunkel SL, Danforth JM, Goodman RE, Standiford TJ (1995) Neutralization of IL-10 increases survival in a murine model of Klebsiella pneumonia. J Immunol 155:722–729PubMedGoogle Scholar
  38. 38.
    Ku¨hn R, Lohler J, Rennick D, Rajewsky K, Muller W (1993) Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75:263–274CrossRefGoogle Scholar
  39. 39.
    Opal SM, De Pa VA (2000) Anti-inflammatory cytokines. Chest 117:1162–1172CrossRefPubMedGoogle Scholar
  40. 40.
    Baier RJ, Loggins J, Yanamandra K (2006) IL-10, IL-6 and CD14 polymorphisms and sepsis outcome in ventilated very low birth weight infants. BMC Med 4:1–11CrossRefGoogle Scholar
  41. 41.
    De Waal Malefyt R, Abrams J, Bennett B, Figdor CG, De Vries JE (1991) Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 174:1209–1220CrossRefPubMedGoogle Scholar
  42. 42.
    Murray PJ, Wang L, Onufryk C, Tepper RI, Young RA (1997) T cell-derived IL-10 antagonizes macrophage function in mycobacterial infection. J Immunol 158:15–21Google Scholar
  43. 43.
    Llorente L, Richaud-Patin Y, Fior R, Alcocer-Varela J, Wijdenes J, Fourrier BM, Galanaud P, Emilie D (1994) In vivo production of interleukin-10 by non-T cells in rheumatoid arthritis, Sjogren’s syndrome, and systemic lupus erythematosus. A potential mechanism of B lymphocyte hyperactivity and autoimmunity. Arthr Rheum 37:1647–1655CrossRefGoogle Scholar
  44. 44.
    Mason D, Powrie F (1998) Control of immune pathology by regulatory T cells. Curr Opin Immunol 10:649–655CrossRefPubMedGoogle Scholar
  45. 45.
    Kim J, Modlin RL, Moy RL, Dubinett SM, McHugh T, Nickoloff BJ, Uyemura K (1995) IL-10 production in cutaneous basal and squamous cell carcinomas. A mechanism for evading the local T cell immune response. J Immunol 155:2240PubMedGoogle Scholar
  46. 46.
    Miller LC, Lynch EA, Isa S, Logan JW, Dinarello CA, Steere AC (1993) Balance of synovial fluid IL-1 beta and IL-1 receptor antagonist and recovery from lyme arthritis. Lancet 341:146–148CrossRefPubMedGoogle Scholar
  47. 47.
    Girardin E, Roux-Lombard P, Grau GE, Suter P, Gallati H (1992) Imbalance between tumor necrosis factor alpha and soluble TNF receptor levels in severe meningococcemia. Immunology 76:20–23PubMedGoogle Scholar
  48. 48.
    Villard J, Roux-Lombard P, Hugli A, Dayer JM (1993) Could natural inhibitors of tumor necrosis factor alpha modify the clinical course of fulminant meningococcemia? Critical Care Med 21:1396–1400CrossRefGoogle Scholar
  49. 49.
    Spear GT, MEAF A, Cohen MH, Bremer J, Landay AL (2005) Relationship of HIV RNA and cytokines in saliva from HIV-infected individuals. FEMS Immunol Med Microbiol 45:129–136CrossRefPubMedGoogle Scholar
  50. 50.
    Scriba TJ, Zhang HT, Brown HL, Oxenius A, Tamm N, Fidler S, Fox J, Weber JN, Klenerman P, Day CL, Lucas M, Phillips RE (2005) HIV-1—specific CD4+ T lymphocyte turnover and activation increase upon viral rebound. J Clin Invest 115:443–450PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2009

Authors and Affiliations

  • Ranbir Chander Sobti
    • 1
  • Nega Berhane
    • 1
  • Salih Abdul Mahedi
    • 1
  • Rupinder Kler
    • 1
  • Seyed Ali Hosseini
    • 1
  • Vijish Kuttiat
    • 2
  • Ajay Wanchu
    • 2
  1. 1.Department of BiotechnologyPanjab UniversityChandigarhIndia
  2. 2.Department of Internal MedicinePostgraduate Institute of Medical Education and ResearchChandigarhIndia

Personalised recommendations